Sorafenib Long Term Extension Program

Trial Profile

Sorafenib Long Term Extension Program

Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Acronyms STEP
  • Sponsors Bayer
  • Most Recent Events

    • 29 Nov 2017 Planned primary completion date changed from 2 Jun 2018 to 30 Jun 2018.
    • 04 Jan 2017 This trial has been completed in Bulgaria according to European clinical trials database .
    • 30 Jun 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top